Methods for detecting, identifying, and/or quantifying a target molecule in a complex fluid using thermal analysis are disclosed. Exemplary complex fluids include biofluids and environmental fluids. Exemplary target molecules include proteins, peptides, nucleic acids, lipids, carbohydrates, viruses, and combinations thereof. A method for using thermal analysis to determine whether purification affects one or more characteristics, such as binding characteristics, of a target molecule is also disclosed.

Methods for detecting, identifying, and/or quantifying a target molecule in a complex fluid using thermal analysis are disclosed. Exemplary complex fluids include biofluids and environmental fluids. Exemplary target molecules include proteins, peptides, nucleic acids, lipids, carbohydrates, viruses, and combinations thereof. A method for using thermal analysis to determine whether purification affects one or more characteristics, such as binding characteristics, of a target molecule is also disclosed.

The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO:1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map)S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

Some embodiments of the invention include virus-like particle (VLP) binding agents, and related polynucleotides, cells, methods of making, and compositions. Other embodiments of the invention include methods of detecting VLPs, parvovirus, erythrovirus or parvovirus B19 using a VLP binding agent and diagnostic methods for parvovirus, erythrovirus or parvovirus B19. Further embodiments include methods for administering VLP binding agents to an animal. Other embodiments include treating parvovirus, erythrovirus or parvovirus B19 infections and other diseases. Additional embodiments of the invention are also discussed.

Sized-based detection techniques for detection of bio-nanoparticles are described. Detection nanoparticles and methods of forming the detection nanoparticles that can be utilized in the techniques are described. Detection nanoparticles can include modified bacteriophage that express a linking agent for a specific binding agent. Detection nanoparticles can bind a functional bio-nanoparticle with high specificity through specific binding of one or more entities unique to the functional bio-nanoparticle of interest. A detection nanoparticle can target an entity of a bio-nanoparticle that is relevant to its function, and as such, the methods can provide improvements in detection of complete and functional bio-nanoparticles. Size-based detection regimes can include particle displacement measurement techniques based upon Brownian motion.

Methods for predicting the development of sepsis in a subject at risk for developing sepsis are provided. In one method, features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. In one method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods of diagnosing sepsis in a subject are provided. In one such method, a plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set.

Provided herein are, inter alia, antibodies, antigen-binding antibody fragments, cells, polynucleotides, compositions, kits, and methods relating to the detection of HBV protein X (HBx), e.g., in vitro and in vivo. Included are antibodies and fragments thereof that bind HBx, as well as kits, cells, and compositions comprising such antibodies and fragments.

The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.

A method for image analysis of medical test results, comprising receiving, at a server, information from a mobile device regarding test results from a test performed using a testing device, wherein the testing device includes an alignment target disposed on the testing device and a plurality of immunoassay test strips, receiving at the server an image of the testing device from the mobile device, determining by the server RGB values for a plurality of pixels of the image, normalizing by the server the RGB values into a single value, comparing by the server the single value to a control value stored on the server, and providing by the server a risk indicator, wherein the risk indicator indicates a likelihood of a presence of a medical condition.

Transcriptional units encoding Zika virus (ZIKV) premembrane (prM) and envelope (E) proteins, which upon translation form Zika virus-like particles (VLPs), are described. Use of the transcriptional units and VLPs in three different ZIKV vaccine platforms is described. Immunoassay-based detection methods using ZIKV VLPs are described for the diagnosis of ZIKV infection.